Remsima - direct healthcare professional communication (DHPC)

infliximab
DHPCHuman

Greek is available via eTranslation, the European Commission's machine translation service.

Translate to Greek | Important information about machine translation

Περί

This direct healthcare professional communication (DHPC) contains important information for healthcare professionals prescribing, dispensing or administering the medicine(s). It also includes a communication plan with details of intended recipients and the dissemination date.

Έγγραφα

Direct healthcare professional communication (DHPC) : Remsima (infliximab): New IV formulation (100 mg and 350 mg concentrate for solution for infusion) contains sorbitol and is therefore contraindicated in patients with hereditary fructose intolerance

English (EN) (154.65 KB - PDF)

Δημοσιεύθηκε για πρώτη φορά:
Προβολή

Key facts

Medicine name
Remsima
Active substance
infliximab
Therapeutic area (MeSH)
  • Arthritis, Psoriatic
  • Spondylitis, Ankylosing
  • Colitis, Ulcerative
  • Psoriasis
  • Crohn Disease
  • Arthritis, Rheumatoid
Procedure number
X-149
Regulatory outcome
Variation
DHPC type
New contraindication
Human ATC codes
L04AB02
Dissemination date

Share this page